

Author index

Volume 71 (2006)

- Agbaria, R., see Marquez, V.E. 71, 268
- Andrei, G., see Balzarini, J. 71, 75
- Andrei, G., Three-dimensional culture models for human viral diseases and antiviral drug development 71, 96
- Ang, T.H., see Tan, T.M.C. 71, 7
- Aquaro, S., see Perno, C.F. 71, 293
- Baba, M., Recent status of HIV-1 gene expression inhibitors 71, 301
- Bai, J., see Tan, T.M.C. 71, 7
- Bailey, K., see Barnard, D.L. 71, 53
- Balzarini, J., G. Andrei, L. Naesens, J. Neyts, C. Pannecouque, D. Schols, R. Snoeck, Introduction to the Special Issue dedicated to Prof. Erik De Clercq for reaching the Professor Emeritus status at the Katholieke Universiteit Leuven 71, 75
- Balzarini, J., Inhibition of HIV entry by carbohydrate-binding proteins 71, 237
- Balzarini, J., see de Castro, S. 71, 15
- Balzarini, J., see McGuigan, C. 71, 149
- Balzarini, J., see Meier, C. 71, 282
- Balzarini, J., see Perno, C.F. 71, 293
- Barnard, D.L., C.W. Day, K. Bailey, M. Heiner, R. Montgomery, L. Lauridsen, S. Winslow, J. Hoopes, J.K.-K. Li, J. Lee, D.A. Carson, H.B. Cottam, R.W. Sidwell, Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin 71, 53
- Barnard, D.L., see Sidwell, R.W. 71, 379
- Billiau, A., Anti-inflammatory properties of Type I interferons 71, 108
- Biron, K.K., Antiviral drugs for cytomegalovirus diseases 71, 154
- Biswas, S., see Field, H.J. 71, 127
- Camarasa, M.-J., S. Velázquez, A. San-Félix, M.-J. Pérez-Pérez, F. Gago, Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: A single mode of inhibition for the three HIV enzymes? 71, 260
- Camarasa, M.-J., see de Castro, S. 71, 15
- Carson, D.A., see Barnard, D.L. 71, 53
- Castanho, M.A.R.B., see Veiga, A.S. 71, 69
- Chen, Y., see Tan, T.M.C. 71, 7
- Cheung, P.K., see Kagan, R.M. 71, 42
- Coplan, P., see Martinez, J. 71, 343
- Cottam, H.B., see Barnard, D.L. 71, 53
- Day, C.W., see Barnard, D.L. 71, 53
- de Castro, S., C. García-Aparicio, K. Van Laethem, F. Gago, E. Lobatón, E. De Clercq, J. Balzarini, M.-J. Camarasa, S. Velázquez, Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile 71, 15
- De Clercq, E., see de Castro, S. 71, 15
- Fan, X., X. Zhang, L. Zhou, K.A. Keith, E.R. Kern, P.F. Torrence, Assembling a smallpox biodefense by interrogating 5-substituted pyrimidine nucleoside chemical space 71, 201
- Fang, P., see Xie, Y.-Y. 71, 31
- Field, H.J., S. Biswas, I.T. Mohammad, Herpesvirus latency and therapy—From a veterinary perspective 71, 127
- Gago, F., see Camarasa, M.-J. 71, 260
- Gago, F., see de Castro, S. 71, 15
- García-Aparicio, C., see de Castro, S. 71, 15
- Golankiewicz, B., T. Ostrowski, Tricyclic nucleoside analogues as antiherpes agents 71, 134
- Gosselin, G., see Mathé, C. 71, 276
- Griffiths, P.D., Antivirals in the transplant setting 71, 192
- Gubareva, L.V., see Mishin, V.P. 71, 64
- Haagmans, B.L., A.D.M.E. Osterhaus, Coronaviruses and their therapy 71, 397
- Harden, E.A., see Prichard, M.N. 71, 1
- Hayden, F.G., Antivirals for influenza: Historical perspectives and lessons learned 71, 372
- Hayden, F.G., see Mishin, V.P. 71, 64
- Heiner, M., see Barnard, D.L. 71, 53
- Herdeewijn, P., The interplay between antiviral activity, oligonucleotide hybridisation and nucleic acids incorporation studies 71, 317
- Hernandez-Santiago, B.I., see Schinazi, R.F. 71, 322
- Holý, A., Antiviral acyclic nucleoside phosphonates structure activity studies 71, 248
- Hoopes, J., see Barnard, D.L. 71, 53
- Huang, Z., M.G. Murray, J.A. Secrist III, Recent development of therapeutics for chronic HCV infection 71, 351
- Huard, T.K., see Kagan, R.M. 71, 42
- Hughes, S.H., see Marquez, V.E. 71, 268
- Hurwitz, S.J., see Schinazi, R.F. 71, 322
- Jiang, L.-P., see Xie, Y.-Y. 71, 31
- Kagan, R.M., P.K. Cheung, T.K. Huard, M.A. Lewinski, Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment 71, 42
- Keith, K.A., see Fan, X. 71, 201
- Keith, K.A., see Prichard, M.N. 71, 1
- Keith, K.A., see Quenelle, D.C. 71, 24
- Kern, E.R., Pivotal role of animal models in the development of new therapies for cytomegalovirus infections 71, 164
- Kern, E.R., see Fan, X. 71, 201
- Kern, E.R., see Prichard, M.N. 71, 1
- Kern, E.R., see Quenelle, D.C. 71, 24
- Kong, K.H., see Tan, T.M.C. 71, 7
- Lam, Y., see Tan, T.M.C. 71, 7
- Lauridsen, L., see Barnard, D.L. 71, 53

- Lee, J., see Barnard, D.L. 71, 53
- Lee, W.A., J.C. Martin, Perspectives on the development of acyclic nucleotide analogs as antiviral drugs 71, 254
- Lenaerts, L., L. Naesens, Antiviral therapy for adenovirus infections 71, 172
- Lewinski, M.A., see Kagan, R.M. 71, 53
- Li, J.K.-K., see Barnard, D.L. 71, 53
- Li, Y., see Tan, T.M.C. 71, 7
- Lim, S.G., see Tan, T.M.C. 71, 7
- Liu, H.-L., see Xie, Y.-Y. 71, 31
- Lobatón, E., see de Castro, S. 71, 15
- Marquez, V.E., S.H. Hughes, S. Sei, R. Agbaria, The history of N-methanocar-bathymidine: The investigation of a conformational concept leads to the dis-covery of a potent and selective nucleoside antiviral agent 71, 268
- Martin, J.C., see Lee, W.A. 71, 254
- Martinez, J., P. Coplan, M.A. Wainberg, Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? 71, 343
- Mathé, C., G. Gosselin, L-Nucleoside enantiomers as antiviral drugs: A mini-review 71, 276
- McGuigan, C., J. Balzarini, Aryl furano pyrimidines: The most potent and selective anti-VZV agents reported to date 71, 149
- Meier, C., J. Balzarini, Application of the *cycloSal*-prodrug approach for improving the biological potential of phosphorylated biomolecules 71, 282
- Mishin, V.P., F.G. Hayden, K.L. Signorelli, L.V. Gubareva, Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection 71, 64
- Mohammad, I.T., see Field, H.J. 71, 127
- Montgomery, R., see Barnard, D.L. 71, 53
- Murray, M.G., see Huang, Z. 71, 351
- Naesens, L., see Balzarini, J. 71, 75
- Naesens, L., see Lenaerts, L. 71, 172
- Neyts, J., see Balzarini, J. 71, 75
- Neyts, J., Selective inhibitors of hepatitis C virus replication 71, 363
- Öberg, B., Rational design of polymerase inhibitors as antiviral drugs 71, 90
- Olsufyeva, E.N., see Preobrazhenskaya, M.N. 71, 227
- Osterhaus, A.D.M.E., see Haagmans, B.L. 71, 397
- Ostrowski, T., see Golankiewicz, B. 71, 134
- Pannecouque, C., see Balzarini, J. 71, 75
- Patick, A.K., Rhinovirus chemotherapy 71, 391
- Pauwels, R., Aspects of successful drug discovery and development 71, 77
- Perno, C.F., V. Svicher, D. Schols, M. Pollicita, J. Balzarini, S. Aquaro, Therapeutic strategies towards HIV-1 infection in macrophages 71, 293
- Pollicita, M., see Perno, C.F. 71, 293
- Preobrazhenskaya, M.N., E.N. Olsufyeva, Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry 71, 227
- Pérez-Pérez, M.-J., see Camarasa, M.-J. 71, 260
- Prichard, M.N., A.D. Williams, K.A. Keith, E.A. Harden, E.R. Kern, Distinct thymidine kinases encoded by cowpox virus and herpes simplex virus con-tribute significantly to the differential antiviral activity of nucleoside analogs 71, 1
- Quenelle, D.C., K.A. Keith, E.R. Kern, In vitro and in vivo evaluation of isatin- β -thiosemicarbazone and marboran against vaccinia and cowpox virus infections 71, 24
- Richman, D.D., Antiviral drug resistance 71, 117
- Robins, M.J., see Wnuk, S.F. 71, 122
- San-Félix, A., see Camarasa, M.-J. 71, 260
- Schinazi, R.F., B.I. Hernandez-Santiago, S.J. Hurwitz, Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses 71, 322
- Schols, D., HIV co-receptor inhibitors as novel class of anti-HIV drugs 71, 216
- Schols, D., see Balzarini, J. 71, 75
- Schols, D., see Perno, C.F. 71, 293
- Secrist III, J.A., see Huang, Z. 71, 351
- Sei, S., see Marquez, V.E. 71, 268
- Shen, K.-L., see Xie, Y.-Y. 71, 31
- Sidwell, R.W., D.L. Barnard, Respiratory syncytial virus infections: Recent prospects for control 71, 379
- Sidwell, R.W., see Barnard, D.L. 71, 53
- Signorelli, K.L., see Mishin, V.P. 71, 64
- Snoeck, R., Papillomavirus and treatment 71, 181
- Snoeck, R., see Balzarini, J. 71, 75
- Svicher, V., see Perno, C.F. 71, 293
- Tan, T.M.C., Y. Chen, K.H. Kong, J. Bai, Y. Li, S.G. Lim, T.H. Ang, Y. Lam, Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substi-tuted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents 71, 7
- Torrence, P.F., see Fan, X. 71, 201
- Van Aerschot, A., Oligonucleotides as antivirals: Dream or realistic perspec-tive? 71, 307
- Van Laethem, K., see de Castro, S. 71, 15
- Vandamme, A.-M., see Vercauteren, J. 71, 335
- Veiga, A.S., M.A.R.B. Castanho, The membranes' role in the HIV-1 neutralizing monoclonal antibody 2F5 mode of action needs re-evaluation 71, 69
- Velázquez, S., see Camarasa, M.-J. 71, 260
- Velázquez, S., see de Castro, S. 71, 15
- Vercauteren, J., A.-M. Vandamme, Algorithms for the interpretation of HIV-1 genotypic drug resistance information 71, 335
- Wainberg, M.A., see Martinez, J. 71, 343
- Wang, L.-J., see Xie, Y.-Y. 71, 31
- Whitley, R.J., Herpes simplex encephalitis: Adolescents and adults 71, 141
- Williams, A.D., see Prichard, M.N. 71, 1
- Winslow, S., see Barnard, D.L. 71, 53
- Wnuk, S.F., M.J. Robins, Ribonucleotide reductase inhibitors as anti-herpes agents 71, 122
- Wu, Y.-P., see Xie, Y.-Y. 71, 31
- Xie, Y.-Y., X.-D. Zhao, L.-P. Jiang, H.-L. Liu, L.-J. Wang, P. Fang, K.-L. Shen, Z.-D. Xie, Y.-P. Wu, X.-Q. Yang, Inhibition of respiratory syncytial virus in cultured cells by nucleocapsid gene targeted deoxyribozyme (DNAzyme) 71, 31
- Xie, Z.-D., see Xie, Y.-Y. 71, 31
- Yang, X.-Q., see Xie, Y.-Y. 71, 31
- Zhang, X., see Fan, X. 71, 201
- Zhao, X.-D., see Xie, Y.-Y. 71, 31
- Zhou, L., see Fan, X. 71, 201
- Zoulim, F., Antiviral therapy of chronic hepatitis B 71, 206